[go: up one dir, main page]

SMT202500069T1 - Composti e composizioni per modulare le attività della chinasi mutante egfr - Google Patents

Composti e composizioni per modulare le attività della chinasi mutante egfr

Info

Publication number
SMT202500069T1
SMT202500069T1 SM20250069T SMT202500069T SMT202500069T1 SM T202500069 T1 SMT202500069 T1 SM T202500069T1 SM 20250069 T SM20250069 T SM 20250069T SM T202500069 T SMT202500069 T SM T202500069T SM T202500069 T1 SMT202500069 T1 SM T202500069T1
Authority
SM
San Marino
Prior art keywords
compositions
compounds
kinase activities
egfr mutant
mutant kinase
Prior art date
Application number
SM20250069T
Other languages
English (en)
Inventor
Byung-Chul Suh
Paresh Devidas Salgaonkar
Jaekyoo Lee
Jong Sung Koh
Ho-Juhn Song
In Yong Lee
Jaesang Lee
Dong Sik Jung
Jung-Ho Kim
Se-Won Kim
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202500069(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of SMT202500069T1 publication Critical patent/SMT202500069T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)
SM20250069T 2014-10-13 2015-10-13 Composti e composizioni per modulare le attività della chinasi mutante egfr SMT202500069T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13
EP21171619.6A EP3929190B1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities

Publications (1)

Publication Number Publication Date
SMT202500069T1 true SMT202500069T1 (it) 2025-03-12

Family

ID=55654993

Family Applications (3)

Application Number Title Priority Date Filing Date
SM20200059T SMT202000059T1 (it) 2014-10-13 2015-10-13 Composti e composizioni per modulare attività chinasiche di egfr mutante
SM20250069T SMT202500069T1 (it) 2014-10-13 2015-10-13 Composti e composizioni per modulare le attività della chinasi mutante egfr
SM20210266T SMT202100266T1 (it) 2014-10-13 2015-10-13 Composti e composizioni per modulare attività chinasiche di egfr mutante.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20200059T SMT202000059T1 (it) 2014-10-13 2015-10-13 Composti e composizioni per modulare attività chinasiche di egfr mutante

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20210266T SMT202100266T1 (it) 2014-10-13 2015-10-13 Composti e composizioni per modulare attività chinasiche di egfr mutante.

Country Status (30)

Country Link
US (2) US9593098B2 (it)
EP (4) EP3207035B1 (it)
JP (3) JP6524221B2 (it)
KR (5) KR20240074820A (it)
CN (2) CN111686110B (it)
AU (1) AU2015331166B2 (it)
BR (1) BR112017007769B1 (it)
CA (1) CA2962914C (it)
CY (2) CY1122737T1 (it)
DK (4) DK3929190T3 (it)
ES (3) ES3009926T3 (it)
FI (3) FI4421069T3 (it)
FR (1) FR25C1021I2 (it)
HR (3) HRP20250213T1 (it)
HU (4) HUE048006T2 (it)
LT (5) LT3929190T (it)
MX (3) MX2017003181A (it)
NL (1) NL301329I2 (it)
NO (1) NO2025025I1 (it)
NZ (1) NZ730012A (it)
PH (1) PH12017500488A1 (it)
PL (3) PL3604294T3 (it)
PT (4) PT3929190T (it)
RS (3) RS66529B1 (it)
RU (1) RU2727700C2 (it)
SG (1) SG11201701960XA (it)
SI (3) SI3604294T1 (it)
SM (3) SMT202000059T1 (it)
TW (2) TWI730331B (it)
WO (1) WO2016060443A2 (it)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3929190T (pt) * 2014-10-13 2025-02-19 Yuhan Corp Compostos e composições para modular atividades da cinase do mutante de egfr
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JP2019501222A (ja) 2016-01-07 2019-01-17 シーエス ファーマテック リミテッド Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
JP7030066B2 (ja) * 2016-05-26 2022-03-04 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Ｅｇｆｒ阻害剤化合物
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
JP7028900B2 (ja) * 2017-06-13 2022-03-02 ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー アミノピリミジン化合物、その調製方法、およびその使用
MX2022008743A (es) * 2017-07-28 2023-02-02 Yuhan Corp Proceso mejorado para preparar derivados de aminopirimidina.
MA49703A (fr) * 2017-07-28 2021-04-21 Yuhan Corp Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci
DK3658547T3 (da) * 2017-07-28 2023-10-16 Yuhan Corp Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
CN111518082B (zh) * 2017-08-30 2021-09-17 深圳市塔吉瑞生物医药有限公司 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN108047207A (zh) * 2018-01-30 2018-05-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
US12336995B2 (en) 2018-09-10 2025-06-24 Mirati Therapeutics, Inc. Combination therapies
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
WO2020125391A1 (zh) * 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
CA3131654A1 (en) 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
HUE073283T2 (hu) * 2019-03-19 2026-01-28 Voronoi Inc Heteroaril-származék, eljárás annak elõállítására és azt hatóanyagként tartalmazó gyógyászati készítmény
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
US12465608B2 (en) 2019-03-29 2025-11-11 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
BR112021022828A2 (pt) * 2019-05-14 2022-04-12 Janssen Biotech Inc Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
CN110128354A (zh) * 2019-06-20 2019-08-16 大连大学 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (ko) * 2020-06-08 2021-12-15 주식회사 종근당 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
US20230321087A1 (en) 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
TWI867047B (zh) * 2020-09-18 2024-12-21 南韓商沃若諾伊公司 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
KR20220085735A (ko) * 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
CN117255792A (zh) * 2021-05-07 2023-12-19 沃若诺伊公司 杂芳基衍生物、其制备方法以及包括其作为活性成分的药物组合物
JP2024519626A (ja) 2021-05-17 2024-05-21 ボロノイ インコーポレイテッド ヘテロアリール誘導体化合物およびその用途｛Ｈｅｔｅｒｏａｒｙｌ ｄｅｒｉｖａｔｉｖｅ ｃｏｍｐｏｕｎｄｓ，ａｎｄ ｕｓｅｓ ｔｈｅｒｅｏｆ｝
CN117425651A (zh) 2021-06-01 2024-01-19 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
US20250205233A1 (en) 2022-03-31 2025-06-26 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
JP2025516171A (ja) 2022-04-28 2025-05-27 アストラゼネカ・アクチエボラーグ 縮合二環式ヘテロ芳香族化合物及び癌の治療におけるその使用
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
MA71241A (fr) 2022-06-27 2025-04-30 Astrazeneca Ab Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer
KR20250044679A (ko) 2022-07-08 2025-04-01 아스트라제네카 아베 암 치료를 위한 hgf-수용체 억제제와 병용의 상피 성장 인자 수용체 티로신 키나아제 억제제
AU2023371904A1 (en) * 2022-11-03 2025-04-17 Voronoi Inc. Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
CN116655600B (zh) * 2023-05-23 2025-08-22 江南大学 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026009146A1 (en) 2024-07-01 2026-01-08 Hetero Labs Limited Benzimidazole compounds as egfr inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9815453A (pt) 1997-03-11 2001-10-23 Du Pont Composto, composição herbicida e método para controle do crescimento de vegetação indesejada
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2002059111A2 (en) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
PL369259A1 (en) 2001-11-01 2005-04-18 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
PL377795A1 (pl) * 2002-11-28 2006-02-20 Schering Aktiengesellschaft Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP4428565B2 (ja) 2004-10-05 2010-03-10 東京エレクトロン株式会社 処理液塗布装置
JP2008515986A (ja) 2004-10-13 2008-05-15 ワイス Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
JP5208516B2 (ja) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (ja) 2005-07-13 2012-08-22 Ｎｔｎ株式会社 グリース組成物および該グリース封入転がり軸受
EP1919470A1 (en) 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS
JP2007117465A (ja) 2005-10-28 2007-05-17 Sharp Corp 集塵器およびそれを備えた電気掃除機
GB2450046B (en) 2006-03-29 2011-03-09 Kt Freetel Co Ltd Digital device and method for providing additional service by using the same
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
EP2004638A1 (en) 2006-04-12 2008-12-24 Wyeth a Corporation of the State of Delaware Anilino-pyrimidine phenyl and benzothiophene analogs
WO2008079291A2 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
MX382352B (es) * 2008-06-27 2025-03-13 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos.
ES2659725T3 (es) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
NZ599041A (en) * 2009-11-13 2014-05-30 Genosco Kinase inhibitors
MX337477B (es) 2011-02-25 2016-03-07 Yuhan Corp Derivados de diaminopiridina y procesos para su preparacion.
LT3333161T (lt) * 2011-07-27 2020-05-11 Astrazeneca Ab 2-(2,4,5-pakeistieji-anilino)pirimidino dariniai kaip egfr moduliatoriai, naudingi vėžio gydymui
ES2668479T3 (es) * 2012-01-20 2018-05-18 Genosco Compuestos de pirimidina sustituidos y su uso como inhibidores de SYK
WO2014040555A1 (zh) * 2012-09-12 2014-03-20 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3036231B1 (en) * 2013-08-22 2020-02-26 Jubilant Biosys Ltd. Substituted pyrimidine compounds, compositions and medicinal applications thereof
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN111875585B (zh) 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
HRP20190407T1 (hr) 2014-06-19 2019-05-03 Ariad Pharmaceuticals, Inc. Heteroarilni spojevi za inhibiciju kinaza
PT3929190T (pt) * 2014-10-13 2025-02-19 Yuhan Corp Compostos e composições para modular atividades da cinase do mutante de egfr
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用

Also Published As

Publication number Publication date
HUE054848T2 (hu) 2021-09-28
SMT202100266T1 (it) 2021-07-12
DK3929190T3 (da) 2025-02-24
KR20210011068A (ko) 2021-01-29
JP2019163277A (ja) 2019-09-26
WO2016060443A2 (en) 2016-04-21
AU2015331166A1 (en) 2017-03-30
US20160102076A1 (en) 2016-04-14
HUE048006T2 (hu) 2020-05-28
RS59900B1 (sr) 2020-03-31
PL3207035T3 (pl) 2020-06-01
NZ730012A (en) 2019-06-28
FR25C1021I1 (fr) 2025-08-01
BR112017007769B1 (pt) 2023-10-10
HRP20200201T1 (hr) 2020-05-15
MX2020002168A (es) 2021-09-07
PT4421069T (pt) 2026-01-12
MX2021010761A (es) 2022-06-09
JP6754864B2 (ja) 2020-09-16
MX385942B (es) 2025-03-18
ES2770058T3 (es) 2020-06-30
CA2962914A1 (en) 2016-04-21
PT3929190T (pt) 2025-02-19
EP3604294A1 (en) 2020-02-05
FR25C1021I2 (fr) 2026-02-06
AU2015331166B2 (en) 2018-04-26
KR102662358B1 (ko) 2024-04-30
KR102487451B1 (ko) 2023-01-11
FIC20250023I1 (fi) 2025-06-06
FI4421069T3 (fi) 2026-01-21
RU2017116598A (ru) 2018-11-21
ES2879474T3 (es) 2021-11-22
RS66529B1 (sr) 2025-03-31
RS61865B1 (sr) 2021-06-30
CY1124359T1 (el) 2022-07-22
LT3929190T (lt) 2025-02-25
TWI730331B (zh) 2021-06-11
PT3604294T (pt) 2021-07-29
EP3604294B1 (en) 2021-05-05
CN111686110A (zh) 2020-09-22
PL3929190T3 (pl) 2025-06-09
TWI664173B (zh) 2019-07-01
EP3929190A1 (en) 2021-12-29
CN106795144B (zh) 2020-06-16
LTPA2025522I1 (it) 2025-06-25
BR112017007769A2 (pt) 2018-01-16
DK4421069T3 (da) 2026-01-19
SI3929190T1 (sl) 2025-04-30
KR20230010836A (ko) 2023-01-19
CY1122737T1 (el) 2021-03-12
SG11201701960XA (en) 2017-04-27
HRP20210949T1 (hr) 2021-09-03
WO2016060443A3 (en) 2016-06-23
SI3207035T1 (sl) 2020-04-30
CN111686110B (zh) 2023-06-16
EP3207035A2 (en) 2017-08-23
HUS2500023I1 (hu) 2025-06-28
JP2017530999A (ja) 2017-10-19
KR20170066650A (ko) 2017-06-14
HUE070874T2 (hu) 2025-07-28
SI3604294T1 (sl) 2021-08-31
ES3009926T3 (en) 2025-03-31
EP4421069A1 (en) 2024-08-28
NO2025025I1 (no) 2025-06-05
DK3604294T3 (da) 2021-06-28
CN106795144A (zh) 2017-05-31
RU2020123547A (ru) 2020-08-18
EP4421069B1 (en) 2025-12-10
JP2020196740A (ja) 2020-12-10
KR102073854B1 (ko) 2020-02-05
FI3929190T3 (fi) 2025-02-28
KR102208775B1 (ko) 2021-01-28
SMT202000059T1 (it) 2020-03-13
JP6524221B2 (ja) 2019-06-05
CA2962914C (en) 2018-10-23
EP3207035B1 (en) 2019-11-20
TW201938553A (zh) 2019-10-01
EP3207035A4 (en) 2018-03-14
HRP20250213T1 (hr) 2025-04-25
EP3929190B1 (en) 2024-12-25
USRE50528E1 (en) 2025-08-12
MX2017003181A (es) 2017-07-20
KR20200014944A (ko) 2020-02-11
LT3604294T (lt) 2021-07-26
RU2017116598A3 (it) 2018-11-21
DK3207035T3 (da) 2020-01-27
TW201619150A (zh) 2016-06-01
LT3207035T (lt) 2020-02-25
RU2727700C2 (ru) 2020-07-23
PL3604294T3 (pl) 2021-11-02
PH12017500488A1 (en) 2017-07-31
LT4421069T (lt) 2026-02-10
KR20240074820A (ko) 2024-05-28
US9593098B2 (en) 2017-03-14
NL301329I2 (nl) 2025-09-09
PT3207035T (pt) 2020-02-19

Similar Documents

Publication Publication Date Title
HUS2500023I1 (hu) Vegyületek és készítmények EGFR mutáns kináz aktivitás modulására
IL286669A (en) Compounds and methods for modulating tmprss6 expression
IL273058A (en) Compositions and methods for modulation of PKK expression
ZA201801600B (en) Compounds and methods for modulating angiotensinogen expression
SG11201802798WA (en) Compounds, compositions, and methods for modulating cftr
IL246879A0 (en) Preparations of Epilimod and methods of using them
ZA201700021B (en) Alk kinase inhibitor, and preparation method and use thereof
HUE037848T2 (hu) Vegyes gyep
SG10202003691PA (en) Composition for modulating irak1
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
GB201614961D0 (en) Compounds and compositions for use
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors